Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.63 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 4/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL22023209 | 0.97 | TDP1 (0.60) | TDP1HSD17B10ALOX15LMNABLM | |
| Trimethylammonium SCHEMBL2433318 | 0.93 | TDP1 (0.55) | TDP1HSD17B10ALOX15LMNABLM | |
| 1,2-Dichloroethane SCHEMBL3832161 | 0.89 | TDP1 (0.71) | TDP1HSD17B10ALOX15LMNABLM | |
| Ethyl Chloride SCHEMBL15846117 | 0.89 | — | — | |
| Butyl Chloride SCHEMBL15846373 | 0.88 | TDP1 (0.55) | TDP1HSD17B10TSHRALDH1A1THRB | |
| Butane SCHEMBL644175 | 0.86 | TDP1 (0.75) | TDP1ALOX15LMNABLMPMP22 | |
| Propane SCHEMBL22974974 | 0.83 | — | — | |
| Propane SCHEMBL28309137 | 0.83 | TDP1 (0.80) | TDP1HSD17B10ALOX15LMNABLM | |
| Acetamide SCHEMBL2373845 | 0.83 | — | — | |
| Hydroxyl Radical SCHEMBL28293952 | 0.83 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260062327-A1 | MEMBRANE TREATMENT OF WATER CONTAINING FREE OIL | ECOLAB USA INC (US) | 2026-03-05 | — | — | US | claimed |
| US-11904525-B2 | Method and system for fabricating cross-layer pattern | STRATASYS LTD. (IL) | 2024-02-20 | — | — | US | claimed |
| EP-3274172-B1 | METHOD AND SYSTEM FOR IN SITU SINTERING OF CONDUCTIVE INK | STRATASYS LTD (IL) | 2023-04-26 | — | — | EP | claimed |
| EP-3947478-A1 | SELF-INVERTING POLYMER EMULSIONS | ChampionX USA Inc. (US) | 2022-02-09 | — | — | EP | claimed |
| US-20260062327-A1 | MEMBRANE TREATMENT OF WATER CONTAINING FREE OIL | ECOLAB USA INC (US) | 2026-03-05 | — | — | US | disclosed |
| US-12173146-B2 | Self-inverting polymer emulsions | CHAMPIONX LLC (US) | 2024-12-24 | — | — | US | disclosed |
| US-11904525-B2 | Method and system for fabricating cross-layer pattern | STRATASYS LTD. (IL) | 2024-02-20 | — | — | US | disclosed |
| CN-114080156-B | Disinfectant composition | 宝洁公司 | 2023-05-23 | — | — | CN | disclosed |
| EP-3274172-B1 | METHOD AND SYSTEM FOR IN SITU SINTERING OF CONDUCTIVE INK | STRATASYS LTD (IL) | 2023-04-26 | — | — | EP | disclosed |
| CN-114746097-A | Use of reboxetine for the treatment of neurological disorders | 艾克萨姆治疗公司 | 2022-07-12 | — | — | CN | disclosed |
| EP-3947478-A1 | SELF-INVERTING POLYMER EMULSIONS | ChampionX USA Inc. (US) | 2022-02-09 | — | — | EP | disclosed |
| US-11242434-B2 | Super-activation of emulsion polymers | ECOLAB USA INC. (US) | 2022-02-08 | — | — | US | disclosed |
| EP-2938641-A1 | MOLECULARLY IMPRINTED POLYMERS AND THEIR USE AS ANTIDANDRUFF AGENTS | L'Oréal (FR) | 2015-11-04 | — | — | EP | disclosed |
| WO-2014102206-A1 | MOLECULARLY IMPRINTED POLYMERS AND THEIR USE AS ANTIDANDRUFF AGENTS | L'OREAL (FR) | 2014-07-03 | — | — | WO | disclosed |
| US-20100081600-A1 | LIQUID DETERGENT COMPOSITIONS EXHIBITING TWO OR MULTICOLOR EFFECT | PROCTER & GAMBLE COMPANY, THE | 2010-04-01 | — | — | US | disclosed |
| US-20100081601-A1 | LIQUID DETERGENT COMPOSITIONS EXHIBITING TWO OR MULTICOLOR EFFECT | PROCTER & GAMBLE COMPANY, THE | 2010-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260062327-A1 | MEMBRANE TREATMENT OF WATER CONTAINING FREE OIL | FGB, EPCAM, F8 | TDP1 2866/4885HSD17B10 3850/4885ALOX15 778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.